Preclinical Testing Services

Welcome to our preclinical testing outsourcing services directory. Preclinical testing plays a critical role in the drug development process, enabling pharmaceutical companies to assess the safety, efficacy, and potential risks associated with new drug candidates before they advance to human trials. Within this directory exists a range of outsourcing partners offering specialized services to address various preclinical testing needs. From in vitro studies to animal model testing, from toxicology assessments to pharmacokinetic analyses, these experts possess the expertise and cutting-edge facilities necessary to support your specific application requirements. Whether you are focused on oncology, cardiovascular diseases, infectious diseases, or other therapeutic areas, this directory provides a comprehensive resource for discovering reliable and accredited service providers that can assist in accelerating your preclinical testing endeavors. By partnering with these industry-leading experts, you can navigate the complexities of preclinical testing with confidence, making informed decisions and optimizing your drug development strategy. Explore our Preclinical Testing Services directory and unlock the potential for success in your research and development initiatives.

  • The Next Test for AI in Pharmacovigilance Is Trust, Not Accuracy

    Monday, September 21, 2026
    An AI model can be right and still not be trusted. That’s what Bristol Myers Squibb (BMS) found six months into rolling out AI-powered adverse event processing: while F1 performance scores were tracking upward, the audit trail found reviewers still reopening cases the system had already cleared. read more
  • Horizon Lines: A Quarterly Review of NDAs – April to June 2026

    Monday, September 21, 2026
    This quarterly review on New Drug Applications contains data for applications approved for the first time during the second quarter of 2026, which includes New Molecular Entities (NMEs) and new biologics. read more
  • The Human Advantage in ADME Testing

    Friday, September 18, 2026
    Animal models do not accurately recapitulate several aspects of human physiology, and these differences lead to variations in drug behaviors across species. Each contributes useful evidence, but what is missing is the connected human biology needed to predict ADME behavior with confidence. read more
  • Upperton Receives MHRA License for Sterile Manufacturing Facility

    Thursday, September 17, 2026
    Upperton has received approval from the U.K. Medicines and Healthcare products Regulatory Agency for a variation to its Manufacturing and Importation Authorisation for Investigational Medicinal Products license covering a new sterile manufacturing facility in Nottingham. read more
  • From Data to Tissue

    Thursday, September 17, 2026
    The national-security regulatory landscape now layers a geopolitical framework onto the data flows, sample logistics, and vendor relationships that make modern clinical research possible. This architecture will not simplify. The DSP’s country-of-concern list may expand, the BIOSECURE Act’s ... read more
  • Disabled_Documentary: A Solid Dosage Future

    In the pharmaceutical manufacturing space, while biopharmaceuticals often dominate discussions, it's crucial to acknowledge the enduring significance of solid dosage products (e.g., tablets, capsules, pills). These traditional forms remain the ...
  • A Solid Dosage Future

    In the pharmaceutical manufacturing space, while biopharmaceuticals often dominate discussions, it's crucial to acknowledge the enduring significance of solid dosage products (e.g., tablets, capsules, pills). These traditional forms remain the ...
We're sorry, no matching articles were found. Please select different filter options and try your search again.
We're sorry, no matching articles were found. Please select different filter options and try your search again.